temozolomide has been researched along with nu 1025 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Boulton, S; Durkacz, BW; Kyle, S | 1 |
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G | 1 |
Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ | 1 |
5 other study(ies) available for temozolomide and nu 1025
Article | Year |
---|---|
Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
Topics: Androstadienes; Animals; Antineoplastic Agents; Cell Survival; CHO Cells; Cricetinae; Dacarbazine; DNA; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Single-Stranded; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Quinazolines; Temozolomide; Wortmannin | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide | 2002 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mutation; Poly (ADP-Ribose) Polymerase-1; PTEN Phosphohydrolase; Quinazolines; Temozolomide; Tumor Suppressor Proteins | 2020 |